Transaction DateRecipientSharesTypePriceValue
22nd December 2020Management Inc. Opaleye496,277Open or private purchase$8.06$3,999,992.62
22nd December 2020Management Inc. Opaleye657Open or private purchase$5.19$3,412.98
22nd December 2020Management Inc. Opaleye15,900Open or private purchase$5.19$82,597.32
21st December 2020Management Inc. Opaleye51,400Open or private purchase$5.24$269,305.16
21st December 2020Management Inc. Opaleye2,059Open or private purchase$5.24$10,787.92
18th December 2020Management Inc. Opaleye35,000Open or private purchase$5.31$185,941.00
18th December 2020Management Inc. Opaleye1,400Open or private purchase$5.31$7,437.64
10th December 2020John Gordon Freund56,327Other acquisition or disposition$0.00
10th December 2020John Gordon Freund118,735Other acquisition or disposition$0.00
3rd December 2020John Gordon Freund47,886Open or private sale$23.39$1,120,197.20
Proteon Therapeutics
Proteon Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.

Proteon Therapeutics, Inc. engages in the research and development of biopharmaceutical products. It produces and commercializes vonapanitase for the treatment of renal and vascular disease. The company was founded by F. Nicholas Franano and William P. Whitaker in 2001.

Ticker: PRTO
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1359931
Employees: 17
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags